Myeloma Patients Europe will hold an online webinar to provide an updated about the current myeloma diagnosis guidelines as well as a review of the current diagnosis techniques.
The talk will be given by Dr Guy Pratt, Honorary Consultant Haematologist at the Heart of England NHS Foundation Trust and Senior Lecturer in Haematology in the Institute of Immunology and Immunotherapy, University of Birmingham. Continue reading
Myeloma Patients Europe (MPE), in close collaboration with Myeloma UK, and along with almost 30 member and non-member associations across Europe, has submitted a letter to the Committee for Human Medicinal Products (CHMP) within the European Medicines Agency (EMA) to encourage them to reconsider the negative recommendation for ixazomib, and provide information to the appeal of their decision on ixazomib. Continue reading
It is with great sadness that we share with you that our friend, colleague and Board member serving as secretary Mrs Christa Kolbe- Geipert passed away last Saturday, 23rd July 2016. Continue reading
Myeloma Patients Europe will hold an online webinar to review the most relevant myeloma updates presented at the annual meeting of the European Hematology Association that took place in Copenhagen in June 2016.
The talk will be given by Dr María Victoria Mateos, PhD. Director of the Myeloma Unit University Hospital of Salamanca-IBSAL Salamanca, Spain Continue reading
MPE is very proud to have been accepted as member of the Patients’ and Consumers’ Working Party (PCWP) at the European Medicines Agency for the term 2016-2019.
The PCWP provides a platform for exchange of information and discussion of issues of common interest between the EMA and patients and consumers. It was established in 2006, and has enabled the Agency to build upon its existing interactions with patients and consumers. It provides recommendations to the EMA and its human scientific committees on all matters of interest in relation to medicines. Continue reading
Ixazomib (Ninlaro) has received a negative recommendation from the Committee for Human Medicinal Products (CHMP) within the European Medicines Agency.
The CHMP is responsible for developing recommendations for the European Commission on new medicines going through the European marketing authorisation process. It assesses and makes recommendations on whether a drug is safe and effective enough to be granted a marketing authorisation for use across the European Union. Usually the European Commission follows the advice of the CHMP. This would mean that ixazomib will not receive European marketing authorisation, and doctors will be unable to routinely prescribe it for their patients. Continue reading
Darzalex® (daratumumab) has today been granted marketing authorisation by the European Commission for use across the European Union. It is specifically indicated for use as a monotherapy (i.e. a treatment which can be given on its own) in relapsed and refractory myeloma patients who have previously been treated with: Continue reading
STATEMENT FROM MYELOMA PATIENTS EUROPE
on the court case it has taken against its
former treasurer Ms Begoña Barragán
Brussels, Belgium – Friday May 20th 2016
Myeloma Patients Europe (MPE) believes it has been defrauded by its former Treasurer Ms Begoña Barragán who, between 2013 and 2014, carried out four unauthorised transfers of money from MPE’s bank account to the Spanish organisations AEAL and Fundaseth, which were under her control and responsibility. In total Ms Barragán transferred eighty-three thousand, seven hundred and fifty EURO (€83,750) into AEAL’s and Fundaseth’s accounts. In addition, Ms Barragán withheld information and documentation about MPE’s financial accounts from the Board, which is the reason why the Board did not discover these disputed financial transactions until after her mandate as MPE treasurer had ended. Continue reading
MPE will be present at the XXXVI World Congress of the International Society of Hematology, hosted by the British Society of Haematology that will take place between the 18 and 21 of April in the Scottish city of Glasgow. Continue reading
New trends in Multiple Myeloma management is to look for the few amounts of cancer cells that might remain in your bone marrow. These residual cells are responsible of the disease relapse. Myeloma Patients Europe will hold an online webinar on Minimal Residual Disease (MRD) that will highlight the importance of this monitoring method and will detail new highly sensitive techniques used to investigate it. Continue reading